BXN Signs Exclusive $7m Manufacturing and Supply Agreement
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Bioxyne Limited has signed an exclusive manufacturing and supply agreement with NectarTek Australia, expected to generate significant revenue for the company in the upcoming fiscal year. The agreement includes minimum order commitments that represent a substantial increase over previous revenues from NectarTek. Bioxyne aims to strengthen its position as a leading manufacturer of alternative pharmaceuticals, including cannabis products, through this partnership. The contract is set to commence in the upcoming fiscal year and may lead to additional long-term contracts as manufacturing capacity expands.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Bioxyne
- Bioxyne Raises A$3 million in Capital Raise
- Trading Halt
- Pause in Trading
- BXN H1 FY25 Results Presentation
- Quarterly Activities Report December 2024 Revised
Later from Bioxyne
- FY25 Revenue Guidance Upgrade
- Certificate GMP Compliance EU, UK, Singapore & Canada
- Enters German Market Euro3.2m Manufacturing & Supply Agmt
- Investor Presentation Update
- Bioxyne Updated Investor Presentation
Follow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne